PATRYS LIMITED
Melbourne, Australia; 12 November, 2014: Patrys Limited (ASX: PAB; Company), a clinical stage biotechnology company, is pleased to announce the appointment, effective from the close of today's 2014 AGM, of Dr. James Campbell as a Non-Executive Director. This appointment strengthens the Board of Patrys as it progresses the clinical development and partnering efforts for its pipeline of clinical and pre-clinical assets.
Dr. Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of several Australian and international biotechnology companies.
Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS), with responsibilities ranging from IP management through to licensing and business development. As a member of the ChemGenex executive team he helped transform a research-based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M.
More recently Dr. Campbell has guided the creation, through acquisition, of Invion Limited (ASX:IVX) as an executive director and remains a non-executive director of that Company, and has assisted private biotechnology companies in New Zealand and the USA with capital raising and partnering negotiations. Dr. Campbell is also a Non-Executive Director of BioProspect Limited (ASX:BPO).
"The Board of Patrys is delighted to have secured the services of Dr. Campbell as we refine our corporate strategy and progress the company's clinical and business development efforts", said Patrys' Chairman, Mr. John Read.
Mr. Read added "James brings substantial and complementary experience to the Patrys Board, including IP management, partnering with global pharmaceutical companies, financial management and strategic transformation within a range of biotech companies. The Board welcomes James and looks forward to his contributions."
Dr. Campbell commented, "I am delighted to join the Board of Patrys at this exciting stage in the company's development. I believe that the company is well positioned to create significant value in the coming year and I look forward to helping guide that progress."
Patrys Limited: | Patrys IR: | Patrys Media: |
Roger McPherson | Kyahn Williamson | Kellie Hanrick |
Interim CEO | Buchan Consulting | Buchan Consulting |
P: +61 3 96703273 | P: +61 3 9866 4722 | P: +61 3 9866 4722 |
info@patrys.com | kwilliamson@buchanwe.com.au | khanrick@buchanwe.com.au |
Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at www.patrys.com
|
distributed by
|
